The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review

In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)...

Descrición completa

Detalles Bibliográficos

Principais autores:	Otasowie Odiase, Lindsay Noah-Vermillion, Brittany A. Simone, Paul D. Aridgides
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2021-05-01
Series:	Frontiers in Oncology
Assuntos:	cervical cancer radiotherapy chemotherapy immunotherapy angiogenesis inhibitors
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2021.663749/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!